Trial Patients
SYSTEMIC HYPERTENSION, TYPE 2 DIABETES
Patients gave written informed consent to participate in the study before any study-related assessments were performed. Patients 40 years and older with systemic hypertension (medicated for more than 1 month) and/or type 2 diabetes were included and had the following at screening or within 6 months prior to screening: elevated blood B-type natriuretic peptide (BNP; 20 pg/mL to 280 pg/mL) or N-terminal pro b-type natriuretic peptide (NT-proBNP; 100 pg/ml to 1000 pg/mL); and enlarged transthoracic left atrial volume index (LAVI; >28 mL/m